Literature DB >> 34446268

Diagnosis and management of an endometrial cancer patient with Cowden syndrome.

Beryl L Manning-Geist1, Sonia Gatius2, Ying Liu3, Mabel Gil4, Arnaud Da Cruz Paula1, Noemi Tuset2, Nadeem R Abu-Rustum1, Carol Aghajanian5, Britta Weigelt6, Xavier Matias-Guiu7.   

Abstract

Somatic PTEN alterations are common in endometrial carcinoma (EC), but in rare cases PTEN mutations are associated with inherited syndromes. Here, we present a case of Cowden syndrome-associated EC. We discuss clinical, pathologic and molecular features of her tumor and PTEN-mutated EC, inherited syndromes predisposing to EC and PTEN-targeted therapies.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cowden syndrome; Germline; PTEN mutation; Pathology; Targeted therapy

Mesh：

Substances：

Year:  2021        PMID： 34446268      PMCID： PMC8515352          DOI： 10.1016/j.ygyno.2021.08.008

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.304


  55 in total

1.  Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  N Colombo; E Preti; F Landoni; S Carinelli; A Colombo; C Marini; C Sessa
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

2.  A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).

Authors:  Vicky Makker; Fernando O Recio; Ling Ma; Ursula A Matulonis; Jennifer O Lauchle; Hema Parmar; Houston N Gilbert; Joseph A Ware; Rui Zhu; Shan Lu; Ling-Yuh Huw; Yulei Wang; Hartmut Koeppen; Jill M Spoerke; Mark R Lackner; Carol A Aghajanian
Journal:  Cancer       Date:  2016-09-07       Impact factor: 6.860

3.  Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

Authors:  Brian M Slomovitz; Yunyun Jiang; Melinda S Yates; Pamela T Soliman; Taren Johnston; Maureen Nowakowski; Charles Levenback; Qian Zhang; Kari Ring; Mark F Munsell; David M Gershenson; Karen H Lu; Robert L Coleman
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

4.  Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities.

Authors:  Judit Pallares; Elena Bussaglia; Jose Luis Martínez-Guitarte; Xavier Dolcet; David Llobet; Montserrat Rue; Lidia Sanchez-Verde; Jose Palacios; Jaime Prat; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

Review 5.  Markers for individualised therapy in endometrial carcinoma.

Authors:  Helga B Salvesen; Ingfrid S Haldorsen; Jone Trovik
Journal:  Lancet Oncol       Date:  2012-08       Impact factor: 41.316

6.  Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.

Authors:  Maria M Rubinstein; David M Hyman; Imogen Caird; Helen Won; Krysten Soldan; Kenneth Seier; Alexia Iasonos; William P Tew; Roisin E O'Cearbhaill; Rachel N Grisham; Martee L Hensley; Tiffany Troso-Sandoval; Paul Sabbatini; Joyce Guillen; S Duygu Selcuklu; Catherine Zimel; Jean Torrisi; Carol Aghajanian; Vicky Makker
Journal:  Cancer       Date:  2019-12-27       Impact factor: 6.860

7.  Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.

Authors:  Benjamin D Hopkins; Chantal Pauli; Xing Du; Diana G Wang; Xiang Li; David Wu; Solomon C Amadiume; Marcus D Goncalves; Cindy Hodakoski; Mark R Lundquist; Rohan Bareja; Yan Ma; Emily M Harris; Andrea Sboner; Himisha Beltran; Mark A Rubin; Siddhartha Mukherjee; Lewis C Cantley
Journal:  Nature       Date:  2018-07-04       Impact factor: 49.962

8.  A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.

Authors:  Takefumi Komiya; Gideon M Blumenthal; Roopa DeChowdhury; Susan Fioravanti; Marc S Ballas; John Morris; Thomas J Hornyak; Stephen Wank; Stephen M Hewitt; Betsy Morrow; Regan M Memmott; Arun Rajan; Phillip A Dennis
Journal:  Oncologist       Date:  2019-07-26

9.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

10.  Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells.

Authors:  John Mark P Pabona; Alexander F Burnett; Dustin M Brown; Charles M Quick; Frank A Simmen; Maria Theresa E Montales; Shi J Liu; Tyler Rose; Iad Alhallak; Eric R Siegel; Rosalia Cm Simmen
Journal:  Reprod Sci       Date:  2020-01-01       Impact factor: 3.060
View more
  1 in total

Review 1.  Hereditary Gynecologic Cancer Syndromes - A Narrative Review.

Authors:  Stoyan Kostov; Rafał Watrowski; Yavor Kornovski; Deyan Dzhenkov; Stanislav Slavchev; Yonka Ivanova; Angel Yordanov
Journal:  Onco Targets Ther       Date:  2022-04-08       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.